Institutional Heavyweights Back Assembly Biosciences’ Dual-Strategy Liver Pipeline
27.05.2026 - 16:04:49 | boerse-global.de
Assembly Biosciences has closed a larger-than-planned equity fundraising, drawing in a roster of blue-chip healthcare investors including Gilead Sciences. The biotech originally targeted around $100 million in gross proceeds but ended up pulling in roughly $115 million after underwriters fully exercised their greenshoe option. The capital injection positions the company to advance two distinct Phase 2 programs targeting both viral and cholestatic liver diseases.
The transaction comprised 3,924,624 common shares sold at $26.50 each, plus 415,000 pre-funded warrants issued at $26.499 per warrant with a nominal exercise price of $0.001. A group of institutional heavyweights participated: Commodore Capital, Farallon Capital Management, Seven Fleet Capital, Sirenia Capital Management, Columbia Threadneedle Investments, Paradigm BioCapital Advisors, Squadron Capital Management, Gilead Sciences, and an unnamed large global fund. After underwriting discounts and estimated expenses, net proceeds came to approximately $107.4 million. Existing shareholders face dilution, but management and directors signed 90-day lock-up agreements, signaling confidence.
Assembly Bio plans to deploy the fresh capital into two clinical studies. The first is a Phase 2 trial of ABI-6250 in patients with chronic hepatitis delta virus infection, slated to begin in the fourth quarter of 2026. The second is a Phase 2 basket study in cholestatic liver diseases — primary biliary cholangitis and primary sclerosing cholangitis — expected to start in the first quarter of 2027. Both timelines are contingent on regulatory feedback. ABI-6250 is an oral small-molecule inhibitor of the sodium-taurocholate cotransporting polypeptide, a membrane protein that shuttles bile acids and also serves as the entry receptor for hepatitis delta virus. The dual mechanism makes it relevant for both viral and non-viral liver indications.
Should investors sell immediately? Or is it worth buying Assembly Biosciences?
The company recently held a pre-IND meeting with the FDA. While the formal minutes are still pending, Assembly described the discussion as constructive, with the agency providing guidance that supports the proposed Phase 2 paths.
Guggenheim Securities and UBS Investment Bank acted as joint bookrunners, with Mizuho as a bookrunner and H.C. Wainwright & Co. as lead manager. H.C. Wainwright analyst Patrick Trucchio reiterated his Buy rating and $50 price target. Across three covering analysts, the consensus average target stands at $48.75 and the stock carries a “Strong Buy” recommendation.
The shelf registration for the securities was declared effective by the SEC on March 27, 2026. After completion of the raise, Assembly Bio now has the financial runway to push both clinical programs forward without near-term funding pressure.
Shares closed at $28.75 on the day of the announcement, up 1.45%. That price sits about 26% below the 52-week high of $38.50 reached in November 2025. The stock has fallen roughly 15% year to date, but over the past twelve months it has still gained 104%. Market capitalization stands at around $553 million. The company also noted that its first-quarter earnings per share beat consensus estimates by $0.10, adding a modest operational bright spot to the financing news.
Ad
Assembly Biosciences Stock: New Analysis - 27 May
Fresh Assembly Biosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
